552 02

Drug Profile

552 02

Alternative Names: 552; CF-552; KM-003; KM-552; KM003/P552; P-552; P-552-02

Latest Information Update: 09 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Parion Sciences
  • Developer Kainos Medicines; Parion Sciences
  • Class Guanidines; Pyrazines; Small molecules
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bronchiectasis; Bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis; Radiation injuries; Xerostomia

Most Recent Events

  • 25 Nov 2014 Discontinued - Preclinical for Bronchiectasis in USA (unspecified route)
  • 25 Nov 2014 Discontinued - Preclinical for Bronchitis in USA (unspecified route)
  • 25 Nov 2014 Discontinued - Preclinical for Radiation injuries in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top